Product Name:Thymosin alpha1
Cas No:62304-98-7
Molar Mass:3108.3
Chemical Formula:C129H215N33O55
Synonyms:Zadaxin
Storage:Store at -20°C
Sequence: SDAAVDTSSEITTKDLKEKKEVVEEAEN
Purity：98%
Application: Thymosin alpha-1 is a synthetic version of a naturally occurring peptide produced by the thymus gland. It plays a crucial role in modulating the immune system by stimulating the production of various immune cells, including T cells, B cells, and natural killer cells. In pharmaceutical chemistry, thymosin alpha-1 is studied for its potential therapeutic applications in boosting immune function and treating immune-related disorders, such as infections, cancer, and autoimmune diseases. It acts by enhancing the body’s defense mechanisms against pathogens and promoting the elimination of abnormal cells. Additionally, thymosin alpha-1 has shown promise in improving vaccine efficacy and reducing the severity of viral infections, including hepatitis B and C, HIV, and influenza. Its mechanism of action in regulating immune responses makes thymosin alpha-1 a valuable candidate for developing treatments in immunology and infectious diseases.
Current Research：
Thymosin alpha 1, a 28-amino acid peptide originally isolated from the thymus, has garnered significant attention for its immune-enhancing, immune-modulating, and immune-restoring properties. Its synthetic form, thymalfasin, has been approved in over 35 countries for the treatment of hepatitis B and C, as well as for immune enhancement in various diseases. Thymosin alpha 1 has demonstrated efficacy in augmenting immune response in immune deficiencies, psoriatic arthritis, aging, and improving response to vaccines. Additionally, it has shown promise in reducing chemotherapy-induced toxicity and treating oncologic patients, particularly those with hepatocellular carcinoma, renal cell carcinoma, and non-small cell lung cancer. Moreover, it has been used in the treatment of numerous infections, including HIV, pseudomonas, mold toxicity, sepsis, and recently in severely ill COVID-19 patients.
Thymosin alpha 1 functions as a toll-like receptor (TLR)-9 and TLR-2 agonist in myeloid and dendritic cells, stimulating the adaptive immune response essential for combating various infections and cancers. It increases levels of cytokines such as IL-2, IL-10, IL-12, interferon (IFN)-α, and IFN-γ, thereby enhancing the immune response. Its ability to stimulate T-cell-dependent antibody production makes it a potential vaccine adjuvant. Thymosin alpha 1 also exhibits anti-tumor activity by inhibiting tumor growth, particularly in lung and liver tumor metastases, and it has anti-proliferative properties against various cancers.
Due to its role in modulating inflammation, immunity, and tolerance, thymosin alpha 1 has been explored as a therapeutic agent for diseases with immune dysfunction. Clinical trials have shown promising results in diseases such as DiGeorge syndrome, non-small cell lung cancer, hepatocellular carcinoma, hepatitis B and C, HIV, and melanoma. The FDA has approved thymalfasin for the treatment of malignant melanoma, chronic active hepatitis B, DiGeorge anomaly with immune defects, and hepatocellular carcinoma due to its immunomodulatory and anti-tumor effects.
Thymosin alpha 1 and its synthetic analogue thymalfasin have well-studied safety profiles and are well-tolerated, with only minor side effects reported. Clinical studies have highlighted their significant role in immune and inflammatory responses, underscoring their potential therapeutic value in a wide range of diseases.
In the context of COVID-19 infection, thymosin alpha 1 has shown promise in reducing mortality in severely ill patients and restoring immune function by increasing thymic activity. Further research is warranted to explore its potential as a therapeutic agent or as part of combination treatments to mitigate the progression and severity of the disease. Overall, thymosin alpha 1 holds promise as a versatile therapeutic agent with diverse applications in immune-related disorders and infectious diseases, including COVID-19.
Target Indicators: Thymosin α1 is a naturally occurring thymic peptide first described and characterized by Goldstein and Goldstein and Garaci Citation.
